WNC 0901
Alternative Names: WNC-0901Latest Information Update: 28 Jun 2024
At a glance
- Originator Waynola Biopharm
- Class Antineoplastics; Radiosensitisers
- Mechanism of Action DNA-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma; Lung cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Glioblastoma in Canada (PO) prior to April 2024
- 05 Apr 2024 Preclinical trials in Lung cancer in Canada (PO) prior to April 2024
- 05 Apr 2024 Pharmacodynamics and pharmacokinetics data from the preclinical trial in glioblastoma and lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research 2024 (AACR-2024)